Non-high-density lipoprotein cholesterol as a risk factor: Addressing risk associated with apolipoprotein B-containing lipoproteins

14Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

There is increasing interest in the use of non-high-density lipoprotein (non-HDL-C) cholesterol as a marker of coronary heart disease risk. Non-HDL-C provides a measure of all apolipoprotein B-containing lipoproteins, including very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), LDL (including small, dense LDL) and lipoprotein(a), all of which have the potential to deliver cholesterol into the arterial wall. This measure thus reflects atherogenic risk not captured by low-density lipoprotein cholesterol (LDL-C) measurement alone, particularly in the context of elevated triglycerides - a setting in which there are increased concentrations of VLDL and atherogenic VLDL remnants. In patients requiring lipid-lowering therapy, non-HDL-C is currently recommended for use as a secondary outcome measure, after LDL-C, in patients with elevated triglycerides. Statins are the most effective agents for reducing levels of atherogenic lipoproteins. Consistent with its distinct pharmacologic properties compared with earlier members of the statin class, rosuvastatin reduces LDL-C significantly more than other statins and produces marked attenuation in atherogenic lipid profiles at a low dose across a wide range of dyslipidaemic phenotypes and patient subpopulations. A recent randomised, double-blind, crossover trial assessed the effects of rosuvastatin 40 mg in hypercholesterolaemic patients with normal triglyceride levels (type IIa dyslipidaemia) or elevated triglyceride levels (type IIb dyslipidaemia). In hypertriglyceridaemic patients, rosuvastatin reduced VLDL1by 46%, VLDL2by 42%, IDL by 54%, LDL by 58% and small, dense LDL by 69%. In normotriglyceridaemic patients, who have lower VLDL and remnant concentrations, rosuvastatin reduced VLDL1by 18%, VLDL2by 26%, IDL by 57%, LDL by 52% and small, dense LDL by 44%. Rosuvastatin thus has the ability to correct substantially the atherogenic lipoprotein profile across a wide range of phenotypes even when elevated concentrations of atherogenic lipoproteins are present as VLDL. © 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Chapman, M. J., & Caslake, M. (2004). Non-high-density lipoprotein cholesterol as a risk factor: Addressing risk associated with apolipoprotein B-containing lipoproteins. In European Heart Journal, Supplement (Vol. 6). https://doi.org/10.1016/j.ehjsup.2004.01.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free